http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2646579-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06c87200cf96acdabeae38cd1101927d
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2535-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2545-114
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2537-165
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-10
filingDate 2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d201b9ad7bb6d97dc3a6d73551c6abb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b70f2a26be1329344e80a19e58fdffb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68e2a8a44ddfc4352da5168e747fcdc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a105278b329b93a73ccff5bc1aef9c8f
publicationDate 2013-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2646579-A1
titleOfInvention Detection of genetic or molecular aberrations associated with cancer
abstract Systems, apparatus, and methods are provided for determining genetic or molecular aberrations in a biological sample from an organism. Biological samples including cell-free DNA fragments are analyzed to identify imbalances in chromosomal regions, e.g., due to deletions and/or amplifications in a tumor. Multiple loci are used for each chromosomal region. Such imbalances can then be used to diagnose (screen) a patient for cancer, as well as prognosticate a patient with cancer, or to detect the presence or to monitor the progress of a premalignant condition in a patient. The severity of an imbalance as well as the number of regions exhibiting an imbalance can be used. A systematic analysis of non-overlapping segments of a genome can provide a general screening tool for a sample. Additionally, a patient can be tested over time to track severity of each of one or more chromosomal regions and a number of chromosomal regions to enable screening and prognosticating, as well as monitoring of progress (e.g. after treatment)
priorityDate 2010-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009013492-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9808980-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398593
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412688

Total number of triples: 33.